Abstracts

Discover the 13 posters and 1 oral presentation that reaffirm Ipsen’s commitment to oncology, its continued investigation into new products and indications.

Liposomal irinotecan

19th January
2018

Poster Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 11:30 - 13:00 and 17:30 - 18:30

BOARD F20 – (Abstract 335)
Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts.
First Author: Shannon Leonard

BOARD H16 – (Abstract 379)
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Teresa Macarulla, MD

BOARD J2 – (Abstract 388)
Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.
First Author: Andrea Wang-Gillam, MD, PhD

BOARD K3 – (Abstract 410)
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal IRI)±5 fluorouracil/leucovorin (5 FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
First Author: Teresa Macarulla, MD

BOARD M6 – (Abstract 459)
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.
First Author: Andrea Wang-Gillam, MD, PhD

BOARD M7 – (Abstract 460)
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI 1: A phase III study of liposomal irinotecan (nal IRI)±5 fluorouracil/leucovorin (5 FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Jens Siveke, Prof. Dr. med.

20th January
2018

Poster Session C - Cancers of the Colon, Rectum, and Anus

Saturday 20th January / 07:00 - 07:55 and 11:30 - 13:00

BOARD G24 – (Abstract 711)
Influence of liposomal irinotecan (nal-IRI) and non-liposomal irinotecan, alone and in combination, on tumor growth and angiogenesis in colorectal cancer (CRC) models.
First Author: Annette Larsen, DVM, PhD

Cabozantinib

19th January
2018

Oral Abstract Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 14:15 - 15:45
Madrid Auditorium

Abstract 207:
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.
First Author: Ghassan Abou-Alfa, MD

19th January
2018

Poster Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 11:30 - 13:00 and 17:30 - 18:30

BOARD A4 – (Abstract 207)
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.
First Author: Ghassan Abou-Alfa, MD

Lanreotide

19th January
2018

Poster Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 11:30 - 13:00 and 17:30 - 18:30

BOARD G8 – (Abstract 347)
Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.
First Author: Edward Wolin, MD

Neuroendocrine Tumors

19th January
2018

Poster Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 11:30 - 13:00 and 17:30 - 18:30

BOARD G20 – (Abstract 359)
Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application.
First Author: Jared Adams, MD, PhD

BOARD E8 – (Abstract 299)
Physical, emotional, and informational challenges of patients living with neuroendocrine tumors in the United States: Understanding their unmet needs.
First Author: Grace Goldstein

Telotristat Ethyl

19th January
2018

Poster Session B - Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Friday 19th January / 11:30 - 13:00 and 17:30 - 18:30

BOARD J9 – (Abstract 395)
Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase III telecast study.
First Author: Joseph Dillon